Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 3Sarcoma 2Pancreatic Neoplasms 2Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Recurrence 1Pleural Effusion, Malignant 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Insulin-Like Growth Factor I, Resistance To 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

ganitumab 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Insulin-Like Growth Factor I, Resistance To × ganitumab × Clear all
NCT00807612 2024-09-25

QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

NantCell, Inc.

Phase 1/2 Terminated
15 enrolled 11 charts

Insulin-Like Growth Factor I, Resistance To

Data powered by HemOnc (CC BY 4.0) Colophon âš¡